title: Effect of brimonidine tartrate 0.10% ophthalmic solution on pupil diameter.
abstract: OBJECTIVE
  To evaluate the effect of brimonidine tartrate 0.10% ophthalmic solution on pupil diameter under light and dark luminance conditions.
  
  
  METHODS
  Ophthalmology Department, Tel Aviv Medical Center, Tel Aviv, Israel.
  
  
  METHODS
  Case series.
  
  
  METHODS
  The pupil diameter was measured with a Colvard pupillometer in eyes of healthy volunteers under light (5.0 candelas [cd]/m(2)) and dark (0.0 cd/m(2)) luminance conditions before brimonidine 0.10% instillation and after 30 minutes, 3 hours, and 6 hours.
  
  
  RESULTS
  The mean age of the 26 volunteers (52 eyes) was 34.73 years (range 19 to 60 years). Under light conditions, the mean pupil diameter was 4.98 mm ± 0.83 (SD) before instillation of brimonidine 0.10% and 4.64 ± 0.82 mm after instillation. The difference was not statistically significant, with 13.4% of eyes having a clinically significant reduction (>1.0 mm) in pupil diameter after 6 hours. Under dark conditions, the mean pupil diameter was 6.76 ± 1.08 mm before instillation of brimonidine 0.10% and 5.30 ± 0.85 mm after instillation; the difference was statistically significant (P<.001). There was a clinically significant reduction in pupil diameter after 6 hours in 90.4% of eyes. The antimydriatic effect under dark luminance conditions was more pronounced in eyes with light irides.
  
  
  CONCLUSIONS
  Brimonidine 0.10% ophthalmic solution had an antimydriatic effect under dark luminance conditions and had a negligible effect on pupil diameter under light luminance conditions. The effect was similar to that reported in studies using higher concentrations of brimonidine.
authors.affiliation: Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Gabi
authors.initials: G
authors.lastname: Shemesh
authors.forename: Elad
authors.initials: E
authors.lastname: Moisseiev
authors.forename: Moshe
authors.initials: M
authors.lastname: Lazar
authors.forename: Anat
authors.initials: A
authors.lastname: Kesler
mesh_terms: D058647:Adrenergic alpha-2 Receptor Agonists / Q000494:pharmacology*; D000328:Adult; D000959:Antihypertensive Agents / Q000494:pharmacology; D000068438:Brimonidine Tartrate; D003623:Dark Adaptation; D003941:Diagnostic Techniques, Ophthalmological / Q000295:instrumentation; D005127:Eye Color; D005260:Female; D006801:Humans; D008027:Light; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000494:pharmacology*; D011680:Pupil / Q000187:drug effects*; D011810:Quinoxalines / Q000494:pharmacology*; D055815:Young Adult
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011810:Quinoxalines; D000068438:Brimonidine Tartrate